

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 2, 2016

**BioCryst Pharmaceuticals, Inc.**

*(Exact Name of Registrant as Specified in Charter)*

**Delaware**  
*(State or Other Jurisdiction  
of Incorporation)*

**000-23186**  
*(Commission  
File Number)*

**62-1413174**  
*(IRS Employer  
Identification No.)*

**4505 Emperor Blvd., Suite 200**  
**Durham, North Carolina 27703**  
*(Address of Principal Executive Offices)*

**(919) 859-1302**  
*(Registrant's telephone number, including area code)*

\_\_\_\_\_  
*(Former Name or Former Address, if Changed Since Last Report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 2, 2016, Charles A. Sanders, M.D. notified BioCryst Pharmaceuticals, Inc. (the “Company”) that he is ready to retire from the Board of Directors of the Company (the “Board”) and he does not intend to stand for re-election at the Company’s Annual Meeting in May 2016. Dr. Sanders stated that he reached this decision because he believes that the Board is well served through the experience and skills of the other Directors on the Company’s Board and therefore it is time for him to retire. Dr. Sanders has served on the Company’s Board of Directors since December 2009 and has been instrumental in assisting the Company in its continued growth and evolution. Dr. Sanders cited no disagreement on any matter relating to the Company, its operations, policies or practices.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 8, 2016

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Alane Barnes  
Alane Barnes  
Vice President, General Counsel and Corporate Secretary